Hospital

Weight loss that began as far as 2 years before a lung cancer diagnosis was associated with a risk of cancer.

Sexual minority populations disproportionately suffer from mental health conditions as well, which could partially impact cardiovascular health, a recent study indicates.

In a single-center study, investigators reviewed charts of 25 children with inflammatory bowel disease transitioning from infliximab to the biosimilar infliximab-dyyb for maintenance.

Structural inequalities that contribute to HIV acquisition are known to also contribute to housing stability, and this was apparent in findings regarding race and ethnicity.

The treatment improved lung function at 12 weeks and quality of life at 4 weeks.

The drug is available in 2 formulations, including a weekly injection with a lower dose than previously available as well as a monthly injection.

EUA restriction for hospitalized patients was basis for lawsuit that advanced several arguments.

Comprehensive in-hospital planning, postdischarge follow-up, ongoing support are key.

The attitudes of community-based opioid use disorder treatment center staff toward the emergency department as a site of initiation were varied, with some feeling that emergency department-initiated buprenorphine may attract patients who were not experiencing life-threatening emergencies.

Reporting vaccination data to Immunization Information Systems databases can support public health surveillance activities.

Specialty pharmacists—those caring for patients with serious, sometimes life-threatening conditions such as cancer or rheumatologic disease—are not immune from the ongoing labor crisis.

The imaging agent and visualization system will be an adjunct to standard of care to reduce residual cancer in the lumpectomy cavity during initial surgery.

Pharmacists should continue to monitor payer policy changes and reimbursement rates and improve understanding of electronic order entry.

The diagnosis should change from an influenza infection if the patient has gradually increasing chest pain after the original diagnosis.

In neonatal intensive care units, probiotic usage was associated with a decline in necrotizing enterocolitis, but not with sepsis or mortality rates.

The risk of long COVID-19 in females in the least deprived areas was comparable to the risk of males in the most deprived areas.

A barrier in effectively treating HIV has been the latency of infected CD4+ T cells, which are often treatment-resistant and contribute to the persistence nature of the virus.

From 2017 to 2021, Australia did not experience a large increase in infections of serotype 19A across all ethnic and age groups, unlike New Zealand.

Long-term data show that early treatment with ofatumumab decreased confirmed disability worsening in nearly all study patients with relapsing multiple sclerosis.

Avapritinib has been FDA approved for the treatment of advanced systemic mastocytosis since June 2021.

Many patients with post-COVID-19 condition reported perceived cognitive deficits early during their COVID-19 infection as well.

Beremagene geperpavec completely closed severe blistering and wounds in more than half of all patients with dystrophic epidermolysis bullosa with specific mutations.

Understanding causes, consequences proves vital to develop therapies that exploit vulnerabilities of the cancer cells.

The results of a recent study suggest that a testing policy change for C. difficile could decrease the risk of additional infections and the corresponding economic burden on the hospital.

Supportive nurse managers and supervisors as well as nurses’ involvement in organizational governance may help lower hospital-onset Clostridioides difficile infection in acute care hospitals.

Findings suggest that mice derived from and breastfed by immunized mothers were capable of producing anti- pneumococcal surface protein A (PspA) specific antibodies, despite having no direct exposure to PspA.

Treatment with epcoritamab-bysp showed a 61% overall response rate and a 38% complete response rate in heavily pretreated patients with R/R DLBCL.

Delivery, manufacturing concerns hinder green light from US Agency, but European Medicines Agency approves treatment.